Impact of Chronic Rhinosinusitis on Long-term Clinical Outcomes in Adults with Asthma
The Journal of Allergy and Clinical Immunology: In Practice · 2026
DOI: 10.1016/j.jaip.2026.01.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Seong-Dae Woo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Allergy, and Critical Care Medicine, Chungnam National University School of Medicine, Daejeon, South Korea. Hauptthemen laut MEDLINE: Asthma, Rhinosinusitis, Sinusitis. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
BACKGROUND: Chronic rhinosinusitis (CRS) is a common comorbidity affecting clinical outcomes in adults with asthma. OBJECTIVE: To assess the impact of CRS on long-term asthma outcomes in a real-world clinical setting. METHODS: This retrospective cohort study analyzed the medical records of 16,153 adults with asthma at the Ajou University Medical Center, Korea. Patients were classified into those with and without comorbid CRS. The CRS group was further stratified into the type 2 (T2)-high and T2-low CRS subgroups based on blood eosinophil counts. Over a 10-year follow-up, long-term clinical outcomes, including asthma exacerbation (AE), hospitalization or emergency department (ED) visits, and systemic corticosteroid use, were estimated using Kaplan-Meier curves and Cox proportional hazards models. We analyzed longitudinal laboratory and lung function measures using adjusted linear mixed-effects models. RESULTS: After propensity score matching, we performed between-group comparisons. The CRS group had higher risks of severe AE (hazard ratio [HR] = 2.07; 95% CI, 1.51-2.87), overall AE (HR = 1.59; 95% CI, 1.36-1.86), hospitalization or ED visits (HR = 1.38; 95% CI, 1.08-1.78), and systemic corticosteroid use (HR = 1.44; 95% CI, 1.25-1.66). Further, these risks were persistently higher in the T2-high CRS subgroup than in the T2-low CRS subgroup (P < .001 for all). Throughout the follow-up, the CRS group, particularly the T2-high subgroup, exhibited elevated blood or sputum eosinophils and FeNO levels, with greater lung function decline than in the non-CRS or T2-low CRS subgroups. CONCLUSION: Comorbid CRS, particularly a T2-high CRS endotype, is associated with increased 10-year risk of AEs, hospitalizations or ED visits, and systemic corticosteroid use, as well as greater lung function decline in adults with asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary, Allergy, and Critical Care Medicine, Chungnam National University School of Medicine, Daejeon, South Korea.
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea.
- Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea. Electronic address: hspark@ajou.ac.kr.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Woo, S. D., Seo, J., Shin, Y. S., Park, R. W., & Park, H. S. (2026). Impact of Chronic Rhinosinusitis on Long-term Clinical Outcomes in Adults with Asthma. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.01.002
Vancouver
Woo SD, Seo J, Shin YS, Park RW, Park HS. Impact of Chronic Rhinosinusitis on Long-term Clinical Outcomes in Adults with Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.01.002
BibTeX
@article{Woo2026,
author = {Woo, Seong-Dae and Seo, Jieun and Shin, Yoo Seob and Park, Rae Woong and Park, Hae-Sim},
title = {Impact of Chronic Rhinosinusitis on Long-term Clinical Outcomes in Adults with Asthma},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
doi = {10.1016/j.jaip.2026.01.002}
}
EUVIMED